Abstract
In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Current Vascular Pharmacology
Title:Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Volume: 12 Issue: 4
Author(s): Manfredi Rizzo, Milan Obradovic, Milica Labudovic-Borovic, Dragana Nikolic, Giuseppe Montalto, Ali A. Rizvi, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Abstract: In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, Obradovic Milan, Labudovic-Borovic Milica, Nikolic Dragana, Montalto Giuseppe, Rizvi A. Ali, Mikhailidis P. Dimitri and Isenovic R. Esma, Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/1570161111999131205160756
DOI https://dx.doi.org/10.2174/1570161111999131205160756 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Current Drug Targets Renal Complications of Fabry Disease
Current Pharmaceutical Design Serum Bilirubin after Acute Ischemic Stroke is Associated with Stroke Severity
Current Neurovascular Research Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Multitasking of Neuropeptide Y through the Lens of Motifs
Recent Patents on CNS Drug Discovery (Discontinued) Indazole Derivatives: Promising Anti-tumor Agents
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design The Role of Pro-Inflammatory Molecules and Pharmacological Agents in Acute Pancreatitis and Sepsis
Inflammation & Allergy - Drug Targets (Discontinued) Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Current Medicinal Chemistry Animal Models for Studying Neointima Formation
Current Vascular Pharmacology PREFACE: “The Lower the Better” Association between White-coat Effect-excluded Blood Pressure and Cardiovascular Events in High-risk Hypertension: Insights from SPRINT
Current Hypertension Reviews Atrial Fibrillation Recurrence: The Roles of Hypertension, Duration of Atrial Fibrillation Disease, and Prolonged Signal-Averaged P Wave Duration
Current Cardiology Reviews PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Current Drug Targets Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research Heme Oxygenase in Regulation of Renal Function and Blood Pressure
Current Hypertension Reviews